Glenmark Pharmaceuticals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Market Cap: ₹63.7K Cr
Glenmark aims for approximately 15% annual sales growth going forward. Glenmark aims for a sales growth of around 15% annually going forward (Page 11 and 19).
From Glenmark Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,318
Market Cap
₹63.7K Cr
P/E Ratio
20.4
Glenmark Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.9K Cr, net profit ₹403 Cr.
Full financials →📊 Revenue & Sales Performance
- →Glenmark aims for approximately 15% annual sales growth going forward. (Page 11)
- →India business showed 17% growth recently and is expected to return to an INR1,150-1,200 crore run rate from Q3 FY '26. (Pages 6, 13)
- →India business revenue is projected to exceed INR4,800 crores in FY '27. (Page 6)
- →U.S. business continues strong growth with upcoming respiratory launches and next 3 Sole FTF/exclusive products. (Page 6)
- →Multi-specific platform assets expected to start entering clinical trials over next 5 years, supporting innovation pipeline growth. (Page 19)
- →Glenmark 3.0 phase expected to be a "glorious phase" over next 5-10 years with transformational growth and transition to a branded-led company globally. (Pages 6, 17)
📈 Profitability & Margins
- →Glenmark aims for a sales growth of around 15% annually going forward (Page 11 and 19).
- →EBITDA margin target is approximately 23% immediately, improving to around 25% in the future (Page 11 and 19).
- →The company expects strong free cash flow generation starting FY '27 and beyond (Page 11 and 19).
- →ROCE is projected to improve from 25% to 30%, with a focus on further enhancement as the portfolio becomes more innovation-driven (Page 19).
- →Glenmark 3.0 phase is expected to bring a robust margin trajectory and strong balance sheet with zero gross debt (Page 8 and 19).
- →The India business is expected to deliver over INR 4,800 crores in top-line revenues in FY '27, supporting overall growth (Page 6).
- →The company anticipates consistent growth in branded portfolio and continued innovation-led value creation (Page 19).
🏗️ Capital Expenditure Plans
- →Glenmark has allocated capital to its subsidiary IGI for capex at about $70 million per annum for the next 3 years, totaling approximately $210-225 million.
- →Most of this capex allocation has been managed through intercompany flows and treasury management within Glenmark entities.
- →The company expects continued investment in innovation, including multi-specific antibody platforms and next-generation programs, with assets entering clinical trials over the next 5 years.
- →Capex spent in H1 FY'26 was around INR 500 crores.
- →Glenmark emphasizes prudent capital allocation going forward focused on organic growth and innovation.
- →The company is targeting strong free cash flow generation while maintaining zero gross debt.
- →There is a focus on building inventories to support growth, considered a normal operational investment.
💰 Fundraising & Capital Structure
- →Glenmark aims to maintain a **zero gross debt balance sheet going forward**, indicating no plans for future debt fundraising.
- →For IGI (a Glenmark subsidiary), the company has **allocated $70 million per annum for the next 3 years** as capital, which will be self-funded through internal resources.
- →Beyond 3 years, IGI might explore additional funding via:
- → - Milestones from partnered assets,
- → - Potential new deals for existing programs,
- → - **Possibly an IPO to raise additional funds**.
- →Overall, Glenmark is focusing on **prudent capital allocation and generating strong free cash flow** to fund business growth.
- →No explicit mention of raising debt or equity at the consolidated Glenmark level in the near term; emphasis is on self-funding and cash generation.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Glenmark Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Glenmark Pharmaceuticals Ltd Q2 FY26 results?
Glenmark aims for approximately 15% annual sales growth going forward. Glenmark aims for a sales growth of around 15% annually going forward (Page 11 and 19).
What is Glenmark Pharmaceuticals Ltd share price analysis?
Glenmark Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹63,749 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glenmark Pharmaceuticals Ltd planning capital expenditure?
Glenmark has allocated capital to its subsidiary IGI for capex at about $70 million per annum for the next 3 years, totaling approximately $210-225 million.
Keep Glenmark Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.